Contact This Organization

Epitel

We at Epitel are democratizing brain health monitoring with a wearable sensor that enables remote patient monitoring. Epitel has built REMI, a simple telehealth platform to quickly screen encephalopathy during an emergency. Two-thirds of Americans, over 218 million people, live >1.5 hour helicopter ride to neuro intensive care. REMI provides community and rural hospitals unprecedented access to remote monitoring of brain activity by epileptologists at neurology clinics.
Mission/Vision
We are bringing to market a simpler, more available alternative to traditional EEG for brain health monitoring
Type of Organization
Startup - Newly established businesses, investable
Size of Organization
0-10
Organization Mailing Address

630 S. Stringfellow Ct., Unit B
Salt Lake City, UT 84111
United States

REMI (Remote EEG Monitoring) with Epilog wearable sensors
REMI is a remote patient monitoring platform that combines Epilog wearable EEG sensors. REMI is specifically targeting community and rural hospital emergency departments and intensive care units that do not have access to an EEG service or neurology. REMI connects epileptologists in tertiary hospitals with the patient at the point-of-care in community and rural hospital ED/ICU staff. The REMI platform reduces misdiagnosis, delayed diagnosis, unnecessary transport, and long-term morbidity.
Category of Innovation
Digital Health - A digital health solution is a technology-based solution whose user is caring for or providing care for themselves (think of a personal app) or another individual (such as a doctor using a tool to help their patient)
Intended End User
Payer - Organizations responsible for issuing or administering payment for the care received by a population of people (e.g. insurance companies)
Patient - Individuals who receive health care
Provider - Individuals or organizations responsible for providing care to patients (e.g. doctors, nurses, hospital/clinic administrators, etc.)
Purchaser - Organizations responsible for purchasing health benefits for a population of people (e.g. employers or government entities)
Policymaker - Elected officials and departments within local, state and federal governments responsible for crafting and implementing health care policy (anyone who has or is campaigning to have a “.gov” email address)
Startup - newly established business, investable
Impactful Innovation Stage (Click Here for Details)
Solution
Problem (i.e. barrier, issue, complication, etc.) being solved for the end user
Two-thirds of the US population live further than a 90 min helicopter ride from neuro intensive care. Community and rural hospitals that service 219 million Americans are incapable of screening for neurological emergencies in these "neurology deserts". Patients suspect of neuro emergencies are transported to large tertiary hospitals for delayed diagnosis. Epitel's REMI platform provides point-of-care remote diagnosis of neuro emergencies. With REMI, Epitel aims to reduce delayed diagnosis, misdiagnosis, unnecessary transport, morbidity, and mortality.
Idea/solution to the problem, if applicable
Epitel's REMI platform provides point-of-care remote diagnosis of neuro emergencies. Similar to "telestroke" consultations, REMI brings epileptologists to community and rural hospital ED/ICUs for a "teleEEG" consultation through remote patient monitoring.
Level of adoption (i.e. list of customers/users, testimonials, etc.), if applicable
* Medtech Innovator Pediatric Accelerator company 2020 cohort
* 435 seizures from 108 children and 77 adults - 904 days of EEG with Epilog sensors
* 1st remote diagnosis of absence epilepsy in a child by an epileptologist in NY during COVID-19 crisis, May 2020
* Pre-submission meeting with FDA, March 2020 (anticipated 510(k) submission, Aug 2020)
* Epilog sensor use in 15 University and Pharmaceutical companies across 5 countries collecting clinical data and for research
* 100% non-dilutive funding - $5M pre-clinical, $2.8M clinical
* MedMountain Ventures committed $100k to this Seed Round
* Ideaship invested $100k in a SAFE for IP strategy and second patent application
* Limited Epilog sensor sales to select university partners beginning Oct 2019
* Vendor presence/presentations at American Epilepsy Society, Epilepsy Foundation Pipeline, Anti-Epileptic Drug and Device Conference since 2013
* Sale of Epoch (pre-clinical) product line to Cage Data Corp, July 2019
* Ideation to Commercialization of Epoch pre-clinical wireless transmitter systems 2009-2018
Funding Stage
Grant funded
List of Funding Sources (if applicable)
National Institutes of Neurological Disorders and Stroke SBIR Phase I/II
Epilepsy Foundation
Certifications?
Yes
Falls with in a predicate 510(k) with FDA (scheduled submission 8/2020)